A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia

This phase I trial evaluated two schedules of escalating vorinostat in combination with decitabine every 28 days: (i) sequential or (ii) concurrent. There were three dose-limiting toxicities: grade 3 fatigue and generalized muscle weakness on the sequential schedule (n = 1) and grade 3 fatigue on th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: How, Jonathan, Minden, Mark D., Brian, Leber, Chen, Eric X., Brandwein, Joseph, Schuh, Andre C., Schimmer, Aaron D., Gupta, Vikas, Webster, Sheila, Degelder, Tammy, Haines, Patricia, Stayner, Lee-Anne, McGill, Shauna, Wang, Lisa, Piekarz, Richard, Wong, Tracy, Siu, Lillian L., Espinoza-Delgado, Igor, Holleran, Julianne L., Egorin, Merrill J., Yee, Karen W. L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4688006/
https://ncbi.nlm.nih.gov/pubmed/25682963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2015.1018248
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados